Cell biology. RIPK3 takes another deadly turn.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

5 citing papers in PubMed.

1. Cross-talk among novel programmed cell death pathways: a decisive network in renal ischemia-reperfusion injury.Frontiers in immunology · 2026
   Review
2. Insights on the crosstalk among different cell death mechanisms.Cell death discovery · 2025
   Review
3. Mechanisms of TNF-independent RIPK3-mediated cell death.The Biochemical journal · 2022
   Review
4. An outline of necrosome triggers.Cellular and molecular life sciences : CMLS · 2016
   Review
5. Molecular crosstalk between apoptosis, necroptosis, and survival signaling.Molecular & cellular oncology
   Review

Corrections and comments

• Comment on
  Activity of protein kinase RIPK3 determines whether cells die by necroptosis or apoptosis.2014

Authors and funding

2 authors.

Funding

Abstract

PubMed holds no abstract for this paper.

Indexed as